Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free RNAC Stock Alerts

Cartesian Therapeutics (RNAC) Competitors

Cartesian Therapeutics logo
$7.39 +0.46 (+6.64%)
Closing price 04:00 PM Eastern
Extended Trading
$7.33 -0.06 (-0.87%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

RNAC vs. IVA, MGTX, GYRE, SLDB, and RLMD

Should you be buying Cartesian Therapeutics stock or one of its competitors? The main competitors of Cartesian Therapeutics include Inventiva (IVA), MeiraGTx (MGTX), Gyre Therapeutics (GYRE), Solid Biosciences (SLDB), and Relmada Therapeutics (RLMD). These companies are all part of the "pharmaceutical products" industry.

How does Cartesian Therapeutics compare to Inventiva?

Cartesian Therapeutics (NASDAQ:RNAC) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 19.1% of Inventiva shares are owned by institutional investors. 60.3% of Cartesian Therapeutics shares are owned by company insiders. Comparatively, 32.0% of Inventiva shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cartesian Therapeutics currently has a consensus target price of $34.00, suggesting a potential upside of 360.08%. Inventiva has a consensus target price of $16.56, suggesting a potential upside of 205.45%. Given Cartesian Therapeutics' higher probable upside, research analysts plainly believe Cartesian Therapeutics is more favorable than Inventiva.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cartesian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Inventiva
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
3 Strong Buy rating(s)
3.10

Cartesian Therapeutics has higher earnings, but lower revenue than Inventiva.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cartesian Therapeutics$1.78M122.33-$130.30M-$5.90N/A
Inventiva$4.48M176.46-$400.67MN/AN/A

Cartesian Therapeutics has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Inventiva has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%.

Company Net Margins Return on Equity Return on Assets
Cartesian Therapeutics-8,550.65% N/A -28.25%
Inventiva N/A N/A N/A

In the previous week, Cartesian Therapeutics had 6 more articles in the media than Inventiva. MarketBeat recorded 8 mentions for Cartesian Therapeutics and 2 mentions for Inventiva. Inventiva's average media sentiment score of 0.69 beat Cartesian Therapeutics' score of -0.35 indicating that Inventiva is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cartesian Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inventiva
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Inventiva beats Cartesian Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Cartesian Therapeutics compare to MeiraGTx?

Cartesian Therapeutics (NASDAQ:RNAC) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Cartesian Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500.

86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 67.5% of MeiraGTx shares are owned by institutional investors. 60.3% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 7.5% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cartesian Therapeutics had 6 more articles in the media than MeiraGTx. MarketBeat recorded 8 mentions for Cartesian Therapeutics and 2 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 0.00 beat Cartesian Therapeutics' score of -0.35 indicating that MeiraGTx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cartesian Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
MeiraGTx
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Cartesian Therapeutics presently has a consensus price target of $34.00, suggesting a potential upside of 360.08%. MeiraGTx has a consensus price target of $25.67, suggesting a potential upside of 163.25%. Given Cartesian Therapeutics' higher possible upside, equities research analysts clearly believe Cartesian Therapeutics is more favorable than MeiraGTx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cartesian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
MeiraGTx
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.75

MeiraGTx has a net margin of -140.31% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat MeiraGTx's return on equity.

Company Net Margins Return on Equity Return on Assets
Cartesian Therapeutics-8,550.65% N/A -28.25%
MeiraGTx -140.31%-1,065.47%-53.33%

MeiraGTx has higher revenue and earnings than Cartesian Therapeutics. MeiraGTx is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cartesian Therapeutics$1.78M122.33-$130.30M-$5.90N/A
MeiraGTx$81.39M9.76-$114.20M-$1.42N/A

Summary

Cartesian Therapeutics and MeiraGTx tied by winning 8 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Gyre Therapeutics?

Cartesian Therapeutics (NASDAQ:RNAC) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Gyre Therapeutics has higher revenue and earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Gyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cartesian Therapeutics$1.78M122.33-$130.30M-$5.90N/A
Gyre Therapeutics$116.59M6.47$5.03M$0.01778.00

Cartesian Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. Comparatively, Gyre Therapeutics has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.

In the previous week, Cartesian Therapeutics had 6 more articles in the media than Gyre Therapeutics. MarketBeat recorded 8 mentions for Cartesian Therapeutics and 2 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.00 beat Cartesian Therapeutics' score of -0.35 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cartesian Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gyre Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 60.3% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 10.0% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Cartesian Therapeutics presently has a consensus price target of $34.00, suggesting a potential upside of 360.08%. Gyre Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 118.51%. Given Cartesian Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cartesian Therapeutics is more favorable than Gyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cartesian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Gyre Therapeutics
2 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

Gyre Therapeutics has a net margin of 4.31% compared to Cartesian Therapeutics' net margin of -8,550.65%. Gyre Therapeutics' return on equity of 10.85% beat Cartesian Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cartesian Therapeutics-8,550.65% N/A -28.25%
Gyre Therapeutics 4.31%10.85%9.16%

Summary

Gyre Therapeutics beats Cartesian Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Solid Biosciences?

Cartesian Therapeutics (NASDAQ:RNAC) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Cartesian Therapeutics had 6 more articles in the media than Solid Biosciences. MarketBeat recorded 8 mentions for Cartesian Therapeutics and 2 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 0.64 beat Cartesian Therapeutics' score of -0.35 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cartesian Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Solid Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cartesian Therapeutics has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.47, suggesting that its stock price is 147% more volatile than the S&P 500.

Cartesian Therapeutics presently has a consensus price target of $34.00, suggesting a potential upside of 360.08%. Solid Biosciences has a consensus price target of $16.09, suggesting a potential upside of 133.20%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Solid Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cartesian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Solid Biosciences
1 Sell rating(s)
0 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.92

Cartesian Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cartesian Therapeutics$1.78M122.33-$130.30M-$5.90N/A
Solid BiosciencesN/AN/A-$174.32M-$2.02N/A

Solid Biosciences has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cartesian Therapeutics-8,550.65% N/A -28.25%
Solid Biosciences N/A -72.23%-59.27%

86.9% of Cartesian Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 60.3% of Cartesian Therapeutics shares are owned by insiders. Comparatively, 1.9% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Cartesian Therapeutics beats Solid Biosciences on 9 of the 16 factors compared between the two stocks.

How does Cartesian Therapeutics compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

In the previous week, Cartesian Therapeutics had 6 more articles in the media than Relmada Therapeutics. MarketBeat recorded 8 mentions for Cartesian Therapeutics and 2 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.00 beat Cartesian Therapeutics' score of -0.35 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Relmada Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cartesian Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Relmada Therapeutics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Relmada Therapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 63.27%. Cartesian Therapeutics has a consensus price target of $34.00, suggesting a potential upside of 360.08%. Given Cartesian Therapeutics' higher probable upside, analysts plainly believe Cartesian Therapeutics is more favorable than Relmada Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Relmada Therapeutics
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
Cartesian Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

Relmada Therapeutics has higher earnings, but lower revenue than Cartesian Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Relmada TherapeuticsN/AN/A-$57.38M-$1.45N/A
Cartesian Therapeutics$1.78M122.33-$130.30M-$5.90N/A

Relmada Therapeutics has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Relmada TherapeuticsN/A -170.83% -145.58%
Cartesian Therapeutics -8,550.65%N/A -28.25%

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Cartesian Therapeutics beats Relmada Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Cartesian Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNAC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNAC vs. The Competition

Export
MetricCartesian TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$217.13M$3.39B$6.25B$11.87B
Dividend YieldN/A2.20%2.73%5.21%
P/E Ratio-1.2538.8529.0428.47
Price / Sales122.33155.53476.6160.94
Price / CashN/A57.8827.6236.52
Price / Book-1.527.039.676.67
Net Income-$130.30M$23.62M$3.55B$332.53M
7 Day Performance8.68%3.67%1.70%2.01%
1 Month Performance18.05%7.16%5.62%9.20%
1 Year Performance-40.59%67.03%34.42%39.59%

Cartesian Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNAC
Cartesian Therapeutics
1.9126 of 5 stars		$7.39
+6.6%		$34.00
+360.1%		N/A$217.13M$1.78MN/A64
IVA
Inventiva
3.0369 of 5 stars		$5.01
-2.3%		$16.56
+230.5%		N/A$748.73M$5.07MN/A100
MGTX
MeiraGTx
2.8434 of 5 stars		$9.08
-0.5%		$25.67
+182.7%		N/A$743.60M$81.39MN/A300
GYRE
Gyre Therapeutics
1.3792 of 5 stars		$7.67
+0.5%		$17.00
+121.6%		N/A$740.06M$116.59M767.7740
SLDB
Solid Biosciences
3.3199 of 5 stars		$7.45
-0.7%		$16.09
+116.0%		N/A$738.10MN/AN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RNAC) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel